<DOC>
	<DOCNO>NCT01222676</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin gemcitabine hydrochloride , work different way stop growth tumor cell , either kill cell stop dividing . Sorafenib tosylate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving cisplatin gemcitabine hydrochloride together sorafenib tosylate may kill tumor cell . Giving surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well give cisplatin gemcitabine hydrochloride together sorafenib tosylate work treat patient node-negative transitional cell cancer bladder .</brief_summary>
	<brief_title>Cisplatin , Gemcitabine Hydrochloride , Sorafenib Tosylate Treating Patients With Transitional Cell Cancer Bladder</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate activity ( pathological complete response ) neoadjuvant cisplatin gemcitabine hydrochloride combination sorafenib tosylate patient muscle-invasive , node-negative transitional cell carcinoma bladder . Secondary - To evaluate safety tolerability regimen patient . - To determine potential biological correlate disease response drug activity tumor tissue sample treatment . - To evaluate correlation fludeoxyglucose F 18 positron emission tomography ( 18FDG-PET ) standard compute tomography ( CT ) result ability change 18FDG-PET ( measure EORTC criterion response ) predict subsequent favorable response treatment ( pathological complete response rate progression-free survival ) . OUTLINE : Patients receive cisplatin IV 20-30 minute day 1 gemcitabine hydrochloride IV 30 minute day 1 8 . Patients also receive sorafenib tosylate twice daily day 1-21. starting day 1and continue Treatment repeat every 21 day 2 course . Patients reassess course 2 , experience disease progression deem unresectable study . Other patient continue treatment 2 courses* . NOTE : *Sorafenib tosylate stop 14 day prior plan cystectomy . No 30 day completion neoadjuvant therapy , patient undergo plan radical cystectomy pelvic lymph-node dissection study . Tumor tissue serum sample may collect study additional biological study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed transitional cell carcinoma ( TCC ) bladder time diagnostic transurethral resection bladder tumor ( TURB ) * Muscleinvasive ( T ≥ 2 ) disease TURB OR clinical stage T3 T4 disease ( e.g. , T2 patient eligible without histological documentation invasive disease ) NOTE : *Confirmation TCC histology base pathologic review Fondazione Istituto Nazionale dei Tumori Milan require case . Clinically nodenegative ( cN0 ) disease PATIENT CHARACTERISTICS : ECOG performance status 01 WBC ≥ 2,000/µL ANC ≥ 1,500/µL Platelet count ≥ 100,000/µL Serum creatinine ≤ 1.5 mg/dL AST/ALT &lt; 2.5 time upper limit normal ( ULN ) ( &lt; 5 time ULN due hepatic metastasis ) Total bilirubin &lt; 1.5 time ULN Not pregnant Negative pregnancy test Fertile patient must use effective contraception Negative serology follow infectious disease : HIV type 1 2 Hepatitis B surface antigen ( active carrier ) Hepatitis C PRIOR CONCURRENT THERAPY : No prior systemic therapy except intravesical therapy superficial disease No prior sorafenib tosylate No prior systemic chemotherapy At least 4 week since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
</DOC>